Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints

by NASDAQ Market News July 28, 2020

NASDAQ Market News
Click here to email author

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research

Ads